Karen Chiang
Manager, Evidence Synthesis
Expertise:
Karen is a Manager on the Value & Evidence team at EVERSANA and has over five years of experience on evidence synthesis projects.
At EVERSANA, Karen has contributed to the development of health economic models, global value dossiers, and indirect treatment comparisons, utilizing extensive knowledge in global systematic and targeted literature reviews to inform HTA submissions and other HEOR activities. Her experience spans several therapeutic areas, including oncology (multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma, prostate cancer, bladder cancer), dermatology (atopic dermatitis), rheumatology (osteoporosis, systemic lupus erythematosus), cardiology (aortic stenosis), neurology (Alzheimer’s disease) and urology (acute kidney injury).
Karen holds a MBiotech degree, specializing in Digital Health Technologies (University of Toronto), and a BSc in Microbiology and Immunology (McGill University).
Articles by Karen Chiang
Treatment Effect Modifiers and Prognostic Factors in Multiple Myeloma: Enabling Smarter Trials and Comparative Research
Multiple myeloma (MM) remains a complex and incurable hematologic malignancy, despite the rapid evolution of therapeutic options over the past decade. With the emergence of novel drug classes—ranging from monoclonal antibody-drug conjugates to CAR-T cell therapies—the treatment landscape has become increasingly intricate, making direct comparisons between regimens challenging. In the absence of head-to-head randomized controlled […]